Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-06 6:07 pm Purchase | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | GOLDMAN SACHS GROUP INC GS | 3,591,860 6.900% | 3,591,860 (New Position) | Filing History |
| 2024-11-04 10:55 am Purchase | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | The Vanguard Group | 2,767,717 5.320% | 2,767,717 (New Position) | Filing History |
| 2024-10-21 4:11 pm Purchase | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BlackRock Inc. BLK | 4,868,789 9.400% | 1,404,202 (+40.53%) | Filing History |
| 2024-02-14 8:51 pm Purchase | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Venrock Healthcare Capital Partners III, L.P. | 4,400,000 8.900% | 1,512,483 (+52.38%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | RA Capital Management, L.P. | 4,163,211 9.700% | 1,373,490 (+49.23%) | Filing History |
| 2024-02-14 4:37 pm Purchase | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Kirn David | 2,033,069 4.700% | 10,571 (+0.52%) | Filing History |
| 2024-02-14 09:56 am Unchanged | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BIOTECHNOLOGY VALUE FUND L P | 4,007,413 9.400% | 0 (Unchanged) | Filing History |
| 2024-02-14 08:43 am Sale | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Deep Track Capital, LP | 2,284,372 5.340% | -372,529 (-14.02%) | Filing History |
| 2024-02-13 10:56 am Purchase | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | JANUS HENDERSON GROUP PLC JHG | 3,093,296 7.200% | 1,627,029 (+110.96%) | Filing History |
| 2024-01-25 4:59 pm Purchase | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BlackRock Inc. BLK | 3,464,587 8.100% | 955,955 (+38.11%) | Filing History |
| 2024-01-08 4:15 pm Sale | 2024-01-04 | 13G | 4D Molecular Therapeutics, Inc. FDMT | VIKING GLOBAL INVESTORS LP | 4,247,914 9.900% | -540,000 (-11.28%) | Filing History |
| 2024-01-08 4:05 pm Purchase | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | VIKING GLOBAL INVESTORS LP | 4,787,914 11.200% | 850,000 (+21.59%) | Filing History |
| 2023-06-05 4:31 pm Purchase | 2023-05-25 | 13G | 4D Molecular Therapeutics, Inc. FDMT | RA Capital Management, L.P. | 2,789,721 6.700% | 2,789,721 (New Position) | Filing History |
| 2023-05-15 4:17 pm Purchase | 2023-05-05 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Venrock Healthcare Capital Partners III, L.P. | 2,887,517 8.700% | 2,887,517 (New Position) | Filing History |
| 2023-02-14 08:32 am Purchase | 2022-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Deep Track Capital, LP | 2,656,901 8.200% | 756,901 (+39.84%) | Filing History |
| 2023-02-09 09:07 am Sale | 2022-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | JANUS HENDERSON GROUP PLC JHG | 1,466,267 4.500% | -181,656 (-11.02%) | Filing History |
| 2023-02-08 4:15 pm Sale | 2022-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Kirn David | 2,022,498 6.200% | -11,877 (-0.58%) | Filing History |
| 2023-01-31 1:58 pm Purchase | 2022-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BlackRock Inc. BLK | 2,508,632 7.700% | 420,950 (+20.16%) | Filing History |
| 2022-06-21 4:53 pm Purchase | 2022-06-16 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BIOTECHNOLOGY VALUE FUND L P | 4,007,413 12.400% | 2,001,551 (+99.79%) | Filing History |
| 2022-02-14 5:02 pm Unchanged | 2021-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | VIKING GLOBAL INVESTORS LP | 3,937,914 12.300% | 0 (Unchanged) | Filing History |